{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:17:00Z","timestamp":1790446620116,"version":"4.1.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,31]],"date-time":"2018-01-31T00:00:00Z","timestamp":1517356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Previously we have reported that metastatic melanoma cell lines and tumor specimens have reduced expression of ADAR1 and consequently are impaired in their ability to perform A-to-I microRNA (miRNA) editing. The effects of A-to-I miRNAs editing on melanoma growth and metastasis are yet to be determined. Here we report that miR-378a\u20133p is undergoing A-to-I editing only in the non-metastatic but not in metastatic melanoma cells. The function of the edited form is different from its wild-type counterpart. The edited form of miR-378a-3p preferentially binds to the 3\u2032-UTR of the <jats:italic>PARVA<\/jats:italic> oncogene and inhibits its expression, thus preventing the progression of melanoma towards the malignant phenotype. Indeed, edited miR-378a-3p but not its WT form inhibits melanoma metastasis in vivo. These results further emphasize the role of RNA editing in melanoma progression.<\/jats:p>","DOI":"10.1038\/s41467-018-02851-7","type":"journal-article","created":{"date-parts":[[2018,1,25]],"date-time":"2018-01-25T17:14:41Z","timestamp":1516900481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":75,"title":["A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression"],"prefix":"10.1038","volume":"9","author":[{"given":"Guermarie","family":"Velazquez-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einav","family":"Shoshan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0168","authenticated-orcid":false,"given":"Cristina","family":"Ivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2529-8256","authenticated-orcid":false,"given":"Enrique","family":"Fuentes-Mattei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrison","family":"Paret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7880-7723","authenticated-orcid":false,"given":"Cristian","family":"Rodriguez-Aguayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Brooks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J. M.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Gordon","family":"Robertson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Calin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Lopez-Berenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Sood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menashe","family":"Bar-Eli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,31]]},"reference":[{"key":"2851_CR1","doi-asserted-by":"crossref","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2017. CA Cancer J. Clin.\u00a067,\u00a07\u201330\u00a0(2017)","DOI":"10.3322\/caac.21387"},{"key":"2851_CR2","doi-asserted-by":"publisher","first-page":"24884","DOI":"10.1074\/jbc.273.38.24884","volume":"273","author":"D Jean","year":"1998","unstructured":"Jean, D., Harbison, M., McConkey, D. J., Ronai, Z. & Bar-Eli, M. CREB and its associated proteins act as survival factors for human melanoma cells. J. Biol. Chem. 273, 24884\u201324890 (1998).","journal-title":"J. Biol. Chem."},{"key":"2851_CR3","doi-asserted-by":"publisher","first-page":"997","DOI":"10.4161\/cbt.7.7.6535","volume":"7","author":"VO Melnikova","year":"2008","unstructured":"Melnikova, V. O. & Bar-Eli, M. Transcriptional control of the melanoma malignant phenotype. Cancer Biol. Ther. 7, 997\u20131003 (2008).","journal-title":"Cancer Biol. Ther."},{"key":"2851_CR4","doi-asserted-by":"publisher","first-page":"2911","DOI":"10.1074\/jbc.M508683200","volume":"281","author":"VO Melnikova","year":"2006","unstructured":"Melnikova, V. O., Mourad-Zeidan, A. A., Lev, D. C. & Bar-Eli, M. Platelet-activating factor mediates MMP-2 expression and activation via phosphorylation of cAMP-response element-binding protein and contributes to melanoma metastasis. J. Biol. Chem. 281, 2911\u20132922 (2006).","journal-title":"J. Biol. Chem."},{"key":"2851_CR5","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1038\/sj.onc.1201358","volume":"15","author":"S Xie","year":"1997","unstructured":"Xie, S. et al. Dominant-negative CREB inhibits tumor growth and metastasis of human melanoma cells. Oncogene 15, 2069\u20132075 (1997).","journal-title":"Oncogene"},{"key":"2851_CR6","doi-asserted-by":"publisher","first-page":"e12452","DOI":"10.1371\/journal.pone.0012452","volume":"5","author":"VO Melnikova","year":"2010","unstructured":"Melnikova, V. O. et al. CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma. PLoS ONE 5, e12452 (2010).","journal-title":"PLoS ONE"},{"key":"2851_CR7","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1083\/jcb.142.3.827","volume":"142","author":"C Bertolotto","year":"1998","unstructured":"Bertolotto, C. et al. Microphthalmia gene product as a signal transducer in cAMP-induced differentiation of melanocytes. J. Cell. Biol. 142, 827\u2013835 (1998).","journal-title":"J. Cell. Biol."},{"key":"2851_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/ncb3110","volume":"17","author":"E Shoshan","year":"2015","unstructured":"Shoshan, E. et al. Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat. Cell. Biol. 17, 311\u2013321 (2015).","journal-title":"Nat. Cell. Biol."},{"key":"2851_CR9","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1172\/JCI62980","volume":"123","author":"Y Nemlich","year":"2013","unstructured":"Nemlich, Y. et al. MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth. J. Clin. Invest. 123, 2703\u20132718 (2013).","journal-title":"J. Clin. Invest."},{"key":"2851_CR10","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1038\/nrm1789","volume":"7","author":"KR Legate","year":"2006","unstructured":"Legate, K. R., Montanez, E., Kudlacek, O. & Fassler, R. ILK, PINCH and parvin: the tIPP of integrin signalling. Nat. Rev. Mol. Cell. Biol. 7, 20\u201331 (2006).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"2851_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00018-005-5355-1","volume":"63","author":"JL Sepulveda","year":"2006","unstructured":"Sepulveda, J. L. & Wu, C. The parvins. Cell. Mol. Life Sci. 63, 25\u201335 (2006).","journal-title":"Cell. Mol. Life Sci."},{"key":"2851_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10549-014-2859-0","volume":"144","author":"M Ito","year":"2014","unstructured":"Ito, M. et al. alpha-Parvin, a pseudopodial constituent, promotes cell motility and is associated with lymph node metastasis of lobular breast carcinoma. Breast Cancer Res. Treat. 144, 59\u201369 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"2851_CR13","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3109\/07357907.2015.1047508","volume":"33","author":"V Bravou","year":"2015","unstructured":"Bravou, V. et al. Focal adhesion proteins alpha- and beta-parvin are overexpressed in human colorectal cancer and correlate with tumor progression. Cancer Invest. 33, 387\u2013397 (2015).","journal-title":"Cancer Invest."},{"key":"2851_CR14","doi-asserted-by":"publisher","first-page":"e0118530","DOI":"10.1371\/journal.pone.0118530","volume":"10","author":"AH Huang","year":"2015","unstructured":"Huang, A. H. et al. PARVA promotes metastasis by modulating ILK signalling pathway in lung adenocarcinoma. PLoS ONE 10, e0118530 (2015).","journal-title":"PLoS ONE"},{"key":"2851_CR15","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1038\/ng.3694","volume":"48","author":"D Kim","year":"2016","unstructured":"Kim, D. et al. General rules for functional microRNA targeting. Nat. Genet. 48, 1517\u20131526 (2016).","journal-title":"Nat. Genet."},{"key":"2851_CR16","doi-asserted-by":"publisher","first-page":"8825","DOI":"10.1007\/s13277-015-4710-6","volume":"37","author":"G Browne","year":"2016","unstructured":"Browne, G. et al. MicroRNA-378-mediated suppression of Runx1 alleviates the aggressive phenotype of triple-negative MDA-MB-231 human breast cancer cells. Tumour Biol. 37, 8825\u20138839 (2016).","journal-title":"Tumour Biol."},{"key":"2851_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep19455","volume":"6","author":"X Chen","year":"2016","unstructured":"Chen, X. et al. miRNA-378 reverses chemoresistance to cisplatin in lung adenocarcinoma cells by targeting secreted clusterin. Sci. Rep. 6, 19455 (2016).","journal-title":"Sci. Rep."},{"key":"2851_CR18","first-page":"7016","volume":"8","author":"B Li","year":"2015","unstructured":"Li, B. et al. Decreased expression of miR-378 correlates with tumor invasiveness and poor prognosis of patients with glioma. Int. J. Clin. Exp. Pathol. 8, 7016\u20137021 (2015).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"2851_CR19","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s13277-015-3996-8","volume":"37","author":"QG Chen","year":"2016","unstructured":"Chen, Q. G. et al. MiR-378 suppresses prostate cancer cell growth through downregulation of MAPK1 in vitro and in vivo. Tumour Biol. 37, 2095\u20132103 (2016).","journal-title":"Tumour Biol."},{"key":"2851_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10993","volume":"7","author":"J Hyun","year":"2016","unstructured":"Hyun, J. et al. MicroRNA-378 limits activation of hepatic stellate cells and liver fibrosis by suppressing Gli3 expression. Nat. Commun. 7, 10993 (2016).","journal-title":"Nat. Commun."},{"key":"2851_CR21","doi-asserted-by":"publisher","first-page":"37309","DOI":"10.1074\/jbc.M112.385229","volume":"287","author":"J Pignatelli","year":"2012","unstructured":"Pignatelli, J., LaLonde, S. E., LaLonde, D. P., Clarke, D. & Turner, C. E. Actopaxin (alpha-parvin) phosphorylation is required for matrix degradation and cancer cell invasion. J. Biol. Chem. 287, 37309\u201337320 (2012).","journal-title":"J. Biol. Chem."},{"key":"2851_CR22","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/hep.26396","volume":"58","author":"L Ng","year":"2013","unstructured":"Ng, L. et al. Suppression of actopaxin impairs hepatocellular carcinoma metastasis through modulation of cell migration and invasion. Hepatology 58, 667\u2013679 (2013).","journal-title":"Hepatology"},{"key":"2851_CR23","doi-asserted-by":"publisher","first-page":"26194","DOI":"10.1074\/jbc.M109.019836","volume":"284","author":"AS Dobroff","year":"2009","unstructured":"Dobroff, A. S. et al. Silencing cAMP-response element-binding protein (CREB) identifies CYR61 as a tumor suppressor gene in melanoma. J. Biol. Chem. 284, 26194\u201326206 (2009).","journal-title":"J. Biol. Chem."},{"key":"2851_CR24","first-page":"2029","volume":"51","author":"RD Zhang","year":"1991","unstructured":"Zhang, R. D., Price, J. E., Schackert, G., Itoh, K. & Fidler, I. J. Malignant potential of cells isolated from lymph node or brain metastases of melanoma patients and implications for prognosis. Cancer Res. 51, 2029\u20132035 (1991).","journal-title":"Cancer Res."},{"key":"2851_CR25","doi-asserted-by":"publisher","first-page":"6910","DOI":"10.1158\/0008-5472.CAN-05-0530","volume":"65","author":"CN Landen Jr","year":"2005","unstructured":"Landen, C. N. Jr et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 65, 6910\u20136918 (2005).","journal-title":"Cancer Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02851-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02851-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,20]],"date-time":"2022-12-20T12:56:41Z","timestamp":1671541001000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-018-02851-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,31]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["2851"],"URL":"https:\/\/doi.org\/10.1038\/s41467-018-02851-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,31]]},"assertion":[{"value":"24 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"461"}}